Praxis Precision Medicines to Present at Two February Investor Conferences
Rhea-AI Summary
Praxis Precision Medicines (NASDAQ: PRAX), a clinical-stage biopharmaceutical company focused on developing CNS disorder therapies, has announced its participation in two upcoming investor conferences in February 2025.
The company will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Conference in New York City on February 6, 2025, at 2:30 p.m. EST, and at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11, 2025, at 11:20 a.m. EST.
One-on-one meetings with investors will be available during both conferences through respective representatives. Live webcasts will be accessible through provided links and the company's website, with replays available for 90 days under the 'Events and Presentations' page in the 'Investors + Media' section.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, PRAX gained 4.02%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BOSTON, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be participating in two upcoming investor conferences:
- Praxis management will be participating in a fireside chat at the Guggenheim Securities SMID Cap Biotechnology Conference, taking place in New York City on February 6, 2025, at 2:30 p.m. EST. A live webcast of the event will be available through this link.
- Praxis management will also be participating in a fireside chat at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place virtually on February 11, 2025, at 11:20 a.m. EST. A live webcast of the event will be available through this link.
The Company will be available for one-on-one meetings during both conferences. Interested investors should contact their respective Guggenheim and/or Oppenheimer representatives to request meetings.
Both webcasts will also be available on the “Events and Presentations” page under the “Investors + Media” section of the company’s website. A replay of the webcasts will be available for 90 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When is Praxis Precision Medicines presenting at the Guggenheim Securities Conference in February 2025?
What is the date and time for PRAX's presentation at the Oppenheimer Healthcare Conference?
How long will the PRAX investor conference webcasts be available for replay?
How can investors arrange one-on-one meetings with PRAX management at the February 2025 conferences?
Where can investors access the live webcasts of PRAX's February 2025 conference presentations?
